论文部分内容阅读
目的观察经门静脉注射重组p53腺病毒(Adv-p53)对肝转移肿瘤的治疗作用。方法通过门静脉注射2×105个MCA-205肿瘤细胞建立小鼠肝转移肿瘤模型,同时将脾脏移植到皮下,作为反复多次向门静脉注射的途径。经门静脉注射不同剂量Adv-p53,注射等体积的平衡盐水或相同剂量的对照腺病毒Adv-CMV作为对照,第21天检查肝脏重量和肝脏转移结节数。结果经门静脉注射1×108 pfu Adv-p53组的肝脏重量为(1.20±0.34)g,明显低于门静脉注射同剂量Adv-CMV组(P<0.05);肝脏转移结节数目为(9.0±9.9)个,明显少于Adv-CMV组(P<0.05)。Adv-p53抑制肝转移肿瘤形成的作用具有剂量效应。在门静脉注射肿瘤细胞的第5天,肝转移肿瘤已经形成,门静脉注射1×108 pfu Adv-p53组的肝脏重量为(1.22±0.09)g,明显低于Adv-CMV组(P<0.05),肝脏转移结节数目(5.5±3.5)明显少于Adv-CMV组(113.2±5.8,P<0.05)。反复多次门静脉注射Adv- p53,可以加强这一抗肿瘤效果。结论通过门静脉系统应用Adv-p53是治疗肝转移肿瘤的有效方法。
Objective To observe the therapeutic effect of recombinant p53 adenovirus (Adv-p53) on hepatic metastases via portal vein. Methods Mouse liver metastasis tumor model was established by injecting 2 × 105 MCA-205 tumor cells through the portal vein. At the same time, the spleen was subcutaneously transplanted into the portal vein as a repeated route. Different doses of Adv-p53 were injected through the portal vein, an equal volume of saline was injected, or the control adenovirus Adv-CMV at the same dose was used as a control. On the 21st day, the liver weights and the number of hepatic metastatic nodules were examined. Results The liver weight of Adv-p53 group (1 × 108 pfu) was (1.20 ± 0.34) g after portal vein injection, which was significantly lower than that of Adv-CMV group (P <0.05). The number of hepatic metastatic nodules was (9.0 ± 9.9) ), Significantly less than Adv-CMV group (P <0.05). Adv-p53 inhibits hepatic metastasis of tumor formation with a dose-response effect. On the fifth day after portal vein injection of tumor cells, liver metastases had formed. The livers in the portal vein injected with 1 × 108 pfu Adv-p53 group (1.22 ± 0.09 g) were significantly lower than those in Adv-CMV group (P <0.05) The number of hepatic metastatic nodes (5.5 ± 3.5) was significantly less than that of Adv-CMV group (113.2 ± 5.8, P <0.05). Repeated portal vein injection of Adv-p53, can enhance the anti-tumor effect. Conclusion The application of Adv-p53 through the portal vein is an effective method for the treatment of liver metastases.